Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (191-200 of 308) with videos related to

Pageof 31
Sort By:
International Journal of Cancer|February 18, 2022
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signatureAnnelie Johansson, Nancy Y Yu, Adina Iftimi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2022
Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT TrialJosephine M N Lopes Cardozo, Caroline A Drukker, Emiel J T Rutgers, et al.
Breast Cancer Research and Treatment|July 27, 2013
The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and careSarah L Elson, Robert A Hiatt, Hoda Anton-Culver, et al.
Breast Cancer Research and Treatment|July 26, 2015
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancerA Jo Chien, Erin Duralde, Richard Hwang, et al.
JAMA Oncology|June 30, 2017
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 DecadesLaura J Esserman, Christina Yau, Carlie K Thompson, et al.
Journal of the National Cancer Institute|December 10, 2024
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trialAnnelie Johansson, Huma Dar, Anna Nordenskjöld, et al.
JAMA Oncology|August 9, 2019
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast CancerNancy Y Yu, Adina Iftimi, Christina Yau, et al.
Journal of Proteome Research|February 9, 2008
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapyJulia D Wulfkuhle, Runa Speer, Mariaelena Pierobon, et al.
Tomography (Ann Arbor, Mich.)|June 18, 2020
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast CancerWen Li, David C Newitt, Bo La Yun, et al.
Journal of the American College of Surgeons|May 30, 2009
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trialJohn A Olson, G Thomas Budd, Lisa A Carey, et al.
Pageof 31

Showing results (191-200 of 308) with videos related to

Sort By:
Pageof 31
International Journal of Cancer|February 18, 2022
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signatureAnnelie Johansson, Nancy Y Yu, Adina Iftimi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2022
Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT TrialJosephine M N Lopes Cardozo, Caroline A Drukker, Emiel J T Rutgers, et al.
Breast Cancer Research and Treatment|July 27, 2013
The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and careSarah L Elson, Robert A Hiatt, Hoda Anton-Culver, et al.
Breast Cancer Research and Treatment|July 26, 2015
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancerA Jo Chien, Erin Duralde, Richard Hwang, et al.
JAMA Oncology|June 30, 2017
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 DecadesLaura J Esserman, Christina Yau, Carlie K Thompson, et al.
Journal of the National Cancer Institute|December 10, 2024
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trialAnnelie Johansson, Huma Dar, Anna Nordenskjöld, et al.
JAMA Oncology|August 9, 2019
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast CancerNancy Y Yu, Adina Iftimi, Christina Yau, et al.
Journal of Proteome Research|February 9, 2008
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapyJulia D Wulfkuhle, Runa Speer, Mariaelena Pierobon, et al.
Tomography (Ann Arbor, Mich.)|June 18, 2020
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast CancerWen Li, David C Newitt, Bo La Yun, et al.
Journal of the American College of Surgeons|May 30, 2009
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trialJohn A Olson, G Thomas Budd, Lisa A Carey, et al.
Pageof 31